Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology Revised Protocol Number 04, incorporating Amendment 05 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0, dated 07-Jan-09)

Next Previous
Trial Profile

A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology Revised Protocol Number 04, incorporating Amendment 05 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0, dated 07-Jan-09)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegdinetanib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use

Most Recent Events

  • 19 Jul 2019 As per European Clinical Trials Database record, trial is completed in UK (End Date: 28 Aug 2013).
  • 01 Aug 2013 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov record.
  • 11 Oct 2012 Planned number of patients changed from 254 to 282.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top